Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by dt_coreon Feb 08, 2011 11:16am
248 Views
Post# 18093948

Interesting timing of deal

Interesting timing of dealThe timing of this deal is curious. Also the use of proceeds was very generic in the press release. Although I'm not a fan of the ~10% dilution, it is possible that HEM is using the proceeds to meet robust customer demand (perhaps undergoing capacity expansion?). If so this is very positive for shareholders, even with the dilution. Without further information though, can't be certain. Also, it is very positive that the deal was done on a bought basis at a very good share price (well above the 15 or 30 day VWAP). This most likely puts a line in the sand as to a base value for the company.

I'll reserve judgment until I hear management's comments on the next conference call. I really want them to provide more detail on use of proceeds. Also, we'll get a much clearer idea of how the whole picture is shaping up for HEM.
Bullboard Posts